摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[Cu(2,3-diphenyl-1,4-diaza-7,10-dioxo-5,6:11,12-dibenzo[e,k]-cyclododeca-1,3-diene[N2O2]ane)(CH3COO)2] | 832692-20-3

中文名称
——
中文别名
——
英文名称
[Cu(2,3-diphenyl-1,4-diaza-7,10-dioxo-5,6:11,12-dibenzo[e,k]-cyclododeca-1,3-diene[N2O2]ane)(CH3COO)2]
英文别名
——
[Cu(2,3-diphenyl-1,4-diaza-7,10-dioxo-5,6:11,12-dibenzo[e,k]-cyclododeca-1,3-diene[N2O2]ane)(CH3COO)2]化学式
CAS
832692-20-3
化学式
C32H28CuN2O6
mdl
——
分子量
600.13
InChiKey
PFQCPPGKXNXOLO-CRLMKPFESA-L
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

反应信息

  • 作为产物:
    描述:
    copper(II) acetate monohydrate 、 2,3-diphenyl-1,4-diaza-7,10-dioxo-5,6:11,12-dibenzo[e,k]-cyclododeca-1,3-diene[N2O2]ane 以 乙醇 为溶剂, 以40%的产率得到[Cu(2,3-diphenyl-1,4-diaza-7,10-dioxo-5,6:11,12-dibenzo[e,k]-cyclododeca-1,3-diene[N2O2]ane)(CH3COO)2]
    参考文献:
    名称:
    电子,循环伏安法,IR和EPR光谱研究带有12元N4,N2O2和N2S2供体大环配体的铜(II)配合物。
    摘要:
    已经合成了一系列新的铜(II)配合物,其大环配体在大环中具有三个不同的供体原子。已经表明,配合物的立体化学取决于配位阴离子。这些复合物的特征在于各种物理化学技术,即。元素分析,摩尔电导,磁化率测量,红外,电子,1H NMR和EPR光谱研究。还讨论了配合物的循环伏安行为。观察到的各向异性g值表明,氯和乙酰复合物是六配位的四边形。硫酸盐和硝酸盐的配合物分别具有五坐标的方形金字塔形和四坐标的方形平面几何形状。
    DOI:
    10.1016/j.saa.2004.04.018
点击查看最新优质反应信息

同类化合物

叔-丁基3-溴-8,9-二氢-5H-[1,2,4]三唑并[4,3-D][1,4]二氮杂卓-7(6H)-甲酸基酯 叔-丁基3-(羟甲基)-7,8-二氢-4H-[1,2,3]三唑并[1,5-A][1,4]二氮杂卓-5(6H)-甲酸基酯 乙基4-(4H-[1,2,4]三唑并[4,3-a][1,5]苯并二氮卓-5-基)哌嗪-1-羧酸酯 9H-[1,2,4]三唑并[4,3-a][1,4]二氮杂卓 9-氯-5,6-二氢-4-甲基-1-(2-噻吩基)-4H-[1,2,4]三唑并[4,3-a][1,5]苯并二氮杂卓 9-氯-1-(2-呋喃基)-5,6-二氢-4-甲基-4H-[1,2,4]三唑并[4,3-a][1,5]苯并二氮杂卓 8-氯-5-(4-甲基哌嗪-1-基)-6-苯基-[1,2,4]三唑并[4,3-a][1,5]苯并二氮杂卓 8-氯-1-甲基-5-(甲基硫烷基)-6-苯基-6H-[1,2,4]三唑并[4,3-a][1,5]苯并二氮卓 2-[(8-氯-6-苯基-6H-[1,2,4]三唑并[4,3-a][1,5]苯并二氮卓-5-基)硫烷基]-N,N-二甲基乙胺 2-[(8-氯-1-甲基-6-苯基-[1,2,4]三唑并[4,3-a][1,5]苯并二氮杂卓-5-基)硫基]-N,N-二甲基乙胺 1H-环丙并[d][1,2,4]三唑并[4,3-b]哒嗪 1H,5H-[1,2,4]三唑并[1,2-a][1,2]二氮杂卓-1,3,5(2H)-三酮,6,9-二氢-2,7-二甲基-9-(2-吡啶基)- (9ci)-1H-1,2,4-噻唑并[4,3-c][1,3]二氮杂卓 (9ci)-1H-1,2,4-噻唑并[4,3-a][1,4]二氮杂卓 3-(Trifluoromethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-D][1,4]diazepine [1,4-dioxy-3-(pyrrolidine-1-carbonyl)-quinoxalin-2-ylmethylene]-hydrazinecarboxylic acid methyl ester 2-methyl-hexahydro-6-thia-2,3a,7c-triaza-4,4e-cyclo-cyclopenta[1,3]cyclopropa[1,2-a]cyclopropa[cd]-as-indacene-1,3-dione 2-methyl-6,6-dioxo-octahydro-6λ6-thia-2,3a,7c-triaza-4,4e-cyclo-cyclopenta[1,3]cyclopropa[1,2-a]cyclopropa[cd]-as-indacene-1,3-dione (4as,4a1r,8aR,13aS)-11-methyldodecahydro-10H-heptaleno[1',10':3,4,5]pyrazolo[1,2-a][1,2,4]triazole-10,12(11H)-dione 8-chloro-1-methyl-6-phenyl-4H-<1,2,4>triazolo<4,3-a><1,5>benzodiazepine-5(6H)-thione N-methyl-4-oxa-8,9,13-triazaheptacyclo<9.5.1.02,6.02,10.06,14.07,12.013,17>heptadecane-8,9-dicarboximide 8-(octyloxy)-4,5-dihydrobenzo[b][1,2,4]triazolo[4,3-d][1,4]thiazepine 1,3,4-trimethyl-7-oxy-8-phenyl-4,6-dihydro-1H-pyrazolo[4,3-e][1,4]diazepin-5-one 7-methyl-6,7-dihydro-5H-benzo[f][1,2,4]triazolo[4,3-d][1,4]diazepine 1-methyl-6-phenyl-4,6-dihydro-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepin-5-one 4,4-dimethyl-10-phenyl-hexahydro-1,7;2,6-dicyclo-dicyclobuta[c,e]cyclopenta[d][1,2,4]triazolo[1,2-a]pyridazine-9,11-dione 2-[3-[(3,4-dichlorophenyl)methyl]-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-N-(oxan-4-yl)-5-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-4-amine 3-{5H,6H,8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-3-yl}azetidine,bis(trifluoroaceticacid) 1-cyclohexyl-4-methyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine 8-chloro-1-cyclohexyl-4-methyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine 2-phenyl-4-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-3H-benzo[b][1,4]diazepine (1α,7α,8β,11β)-syn-14-acetamido-4-methyl-2,4,6-triazatetracyclo<5.4.2.18,11.02,6>tetradecane-3,5-dione 9-chloro-1-(2,4-dichloro-phenyl)-4-methyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine 12-(Hydroxyimino)-5-methyl-3,5,7-triazahexacyclo<7.5.02,13.03,7.08,11.010,14>tetradecane-4,6-dione 4-(benzyloxy)-1-methyl-8-chloro-6-phenyl-4H-s-triazolo[4,3-a][1,5]benzodiazepin-5-one 4-((R)-3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(5,6,7,8-tetrahydro-4H-1,2,3a,6-tetraaza-azulen-3-yl)-3-trifluoromethanesulfonyl-benzenesulfonamide 7-[5-chloro-4-(1-methyl-1H-benzimidazol-2-yl)pyridin-2-yl]-3-cyclopropyl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-d][1,4]diazepine tert-butyl 4-[(1R)-1-({[(6S)-6-(5-chloro-2-methoxybenzyl)-3,7-dioxo-6,7-dihydro-5H-[1,2,4]oxadiazolo[4,3-a][1,4]diazepin-8(9H)-yl]carbonyl}amino)propyl]-2-nitrobenzoate (32Z,51Z,71Z)-35,55,74-trimethyl-1(1,3)-benzena-3,5,7(1,3)-tricyclopentanacyclooctaphane-32,34,51,53,71,74-hexaene 7-methyl-4b,4c,4d,4e,5,8b-hexahydro-5a,7,8a-triaza-4a,5-cyclo-benzo[1,3]cyclopropa[1,2-a]cyclopropa[cd]-as-indacene-2,6,8-trione 2-[3-(2,4-Dibromo-phenyl)-5-phenyl-3H-[1,3,4]thiadiazol-(2E)-ylidene]-pentan-3-one 8-chloro-6-(2-chloro-phenyl)-1-methyl-4,6-dihydro-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepin-5-one 5-methyl-3,5,7-triazahexacyclo<7.5.0.02,13.03,7.08,11.010,14>tetradecane-4,6,12-trione 6,6a,6b,7,8,10,12a,12b-octahydro-2H,5H-bis[1,2,4]triazolo[4,3-a;4',3'-a']cyclobuta[1,2-c;3,4-e']dipyridine-3,11-dione 4-(3-aminopropyl)-1-methyl-8-chloro-6-phenyl-4H-s-triazolo-[4,3-a][1,5]benzodiazepin-5-one